Bellus soars on positive mid-stage readout for its Merck cough rival, despite a failure in atopic dermatitis

Do investors want the good news, or the bad news first? Bellus went with the good news, sharing that its chronic cough contender hit the primary endpoint in a Phase IIb trial, lining it up for a Phase III study in the second half of next year where it could pose stiff competition for Merck.